covid_cell_1_20’s weekly COVID-19 news round-up

pharmafile | February 10, 2021 | News story | Research and Development COVID-19 

The past week has seen lots of positive COVID-19 vaccine news; Oxford University and AstraZeneca have announced development of another vaccine to tackle new COVID-19 mutations, an initial report has suggested that a longer interval between jabs will improve efficacy, and in South Korea a new treatment candidate from Celltrion has been granted marketing authorisation.

1. Longer Oxford-AstraZeneca vaccine interval improves efficacy, report says – Published 03/02/2021

A longer interval between doses of the Oxford University-AstraZeneca vaccine could substantially improve efficacy, according to a report published in the Lancet.

2. New Oxford University-AstraZeneca vaccine against COVID-19 mutations could be available by October – Published 05/02/21

Oxford University and AstraZeneca could release a new vaccine by October in order to counter the new mutations of COVID-19 that have arisen in the UK recently. 

3. South Korea approves Celltrion’s COVID-19 treatment Regdanvimab for emergency use – Published – 08/02/21

The South Korean Ministry of Food and Drug Safety (MFDS) has granted a conditional marketing authorisation (CMA) for the emergency use of Celltrion’s Regdanvimab (CT-P59), a monoclonal antibody COVID-19 treatment candidate.

4. CureVac enters collaboration with UK government on coronavirus variant vaccines– Published 08/02/21

CureVac has entered a collaboration with the UK government to develop and manufacture potential vaccine candidates against coronavirus variants, with the UK set to receive an initial supply of 50 million doses of any vaccines resulting from the partnership.

5. WHO backs AstraZeneca vaccine against South African variant – Published 09/02/21

World health officials have moved to ease concerns over the efficacy of the Oxford University-AstraZeneca vaccine against new variants of COVID-19.

Related Content

FDA approves first oral antiviral to treat adult patients with COVID-19

The US Food and Drug Administration (FDA) has announced that it has approved the oral …


Moderna and Pfizer COVID-19 vaccine protection declines over time

Data presented by Pfizer and Moderna ahead of the FDA’s vaccine advisory committee meeting on …

Sanofi complete acquisition of mRNA company Translate Bio

French pharma giants Sanofi continues its run of acquisitions in 2021 by completing the deal …

Latest content